Liraglutide in the treatment of type 2 diabetes: recommendations for a better patients selection from a multidisciplinary approachArticle list
- F.J. Ampudia-Blasco1, C. Calvo Gómez2, X. Cos Claramunt3, J. García Alegría4, E.Jodar5, J. Navarro6, J.J Mediavilla Bravo7, P. Mezquita8, M. Puig Domingo9
Liraglutide is the first once daily human glucagon-like peptide-1 (GLP-1) analogue, with a 97% homology. Liraglutide has recently been approved by
the European Medicines Agency and by the Food and Drug Administration to be used in the medical management of type 2 diabetes mellitus. Initial approval is for be using in combination with metformin, a sulphonylurea or a combination of metforminwith a sulphonylurea or thiazolidinedione. Monotherapy with liraglutide is also approved in United States. Results from the LEAD (Liraglutide Effect and Action in Diabetes) clinical trials programme
show that liraglutide significantly lowers HbA1c, with a very low risk of hypoglycemia. Liraglutide treatment was also associated with significant and sustained weight loss, decreased systolic blood pressure, improved ¦Â ¦Â-cell function, and reductions in other cardiovascular risk markers. In this article we
review the most up-to-date evidence emanating from the LEAD programme, focussing on practical considerations on how to optimally use this new therapy for type 2 diabetes mellitus.
Correspondencia: Dr. F.J. Ampudia-Blasco. Unidad de Referencia de Diabetes. Servicio de Endocrinología y Nutrición.
Hospital Clínico Universitario de Valencia.
Avda. Blasco Ibáñez, 17. 46010 Valencia.
Correo electrónico: Francisco.J.Ampudia@uv.es
KeywordsGLP- analogues glycemic control type 2 diabetes mellitus incretins liraglutide
(Original in spanish)